Edition:
United States

Stellar Biotechnologies Inc (SBOT.OQ)

SBOT.OQ on NASDAQ Stock Exchange Capital Market

1.84USD
22 Jun 2018
Change (% chg)

$-0.25 (-11.96%)
Prev Close
$2.09
Open
$1.95
Day's High
$1.96
Day's Low
$1.76
Volume
315,837
Avg. Vol
137,234
52-wk High
$10.43
52-wk Low
$1.65

Chart for

About

Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-target... (more)
No analyst recommendations are available for .

Overall

Beta: 2.11
Market Cap(Mil.): $11.52
Shares Outstanding(Mil.): 4.72
Dividend: --
Yield (%): --

Financials

  SBOT.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -3.59 -- --
ROI: -32.77 -5.33 13.09
ROE: -33.17 -6.88 15.10

BRIEF-Sabby Management Llc Reports 9.99 Percent Passive Stake In Stellar Biotechnologies Inc As Of May 11

* SABBY MANAGEMENT, LLC REPORTS 9.99 PERCENT PASSIVE STAKE IN STELLAR BIOTECHNOLOGIES INC AS OF MAY 11, 2018 - SEC FILING Source text - https://bit.ly/2rJNYyF Further company coverage:

May 15 2018

BRIEF-Stellar Acquisition Reduces Extension Date Of Initial Business Combination To August 24

* STELLAR ACQUISITION III INC. ANNOUNCES INCREASE IN MONTHLY CONTRIBUTION AMOUNT TO TRUST ACCOUNT POST-EXTENSION APPROVAL AND SHORTENING OF EXTENSION DATE TO AUGUST 24, 2018 Source text for Eikon: Further company coverage:

May 14 2018

BRIEF-Stellar Biotechnologies Announces Pricing Of $5.5 Mln Public Offering

* STELLAR BIOTECHNOLOGIES ANNOUNCES PRICING OF $5.5 MILLION PUBLIC OFFERING

May 11 2018

BRIEF-Stellar Biotechnologies Reports Q2 Loss Per Share Of $0.90

* STELLAR BIOTECHNOLOGIES REPORTS SECOND QUARTER FINANCIAL RESULTS

May 07 2018

BRIEF-Stellar Biotechnologies Announces One-For-Seven Reverse Split

* STELLAR BIOTECHNOLOGIES ANNOUNCES ONE-FOR-SEVEN REVERSE SPLIT

Apr 27 2018

BRIEF-Stellar Biotechnologies Reports Q1 Loss Per Share $0.13

* STELLAR BIOTECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Feb 07 2018

BRIEF-Stellar Biotechnologies Appoints Pharma Licensing Expert To Board Of Directors

* STELLAR BIOTECHNOLOGIES APPOINTS PHARMA LICENSING EXPERT TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Jan 25 2018

Earnings vs. Estimates

No consensus analysis data available.